(CNN) - Britain's biggest drug company, Glaxo-Smith-Kline, has carried out a clinical trial in Africa that dramatically cut malaria infections in children.
The vaccine almost halved the number of cases in children who got the first jab between the ages of five months and 17 months.
CNN spoke to Dr. David Kaslow, the director of the Path Malaria Vaccine Initiative.
"This translates into really significantly reducing the pain and suffering because malaria continues to be a huge disease burden. About a 1,000 children die every day of malaria in Africa and what this study has also shown is that this vaccine seems to work across a variety of different transmission settings where the disease still occurs in Africa," said Kaslow.
The World Health Organization says more than 600,000 people a year die from malaria, most of them children in sub-Saharan Africa.